Table 5.
Correlation between CK20 mRNA detection in blood and/or bone marrow of esophageal carcinoma patients and clinical parameters.
| Variable | Detection of CK20 mRNA in Blood and/or Bone Marrow (n = 77) | Correlation χ2-Test (p-Value) |
|||
|---|---|---|---|---|---|
| Total | Positive (%) | Negative (%) | |||
| Gender | Female | 13 | 8 (61.54%) | 5 (38.46%) | 0.448 |
| Male | 64 | 32 (50%) | 32 (50%) | ||
| UICC-stage (n = 70) |
I | 16 | 7 (43.75%) | 9 (56.25%) | 0.038 |
| II | 28 | 18 (64.29%) | 10 (35.71%) | ||
| III | 19 | 6 (31.58%) | 13 (68.52%) | ||
| IV | 10 | 8 (80%) | 2 (20%) | ||
| T-category (n = 71) |
I | 18 | 9 (50%) | 9 (50%) | 0.598 |
| II | 23 | 14 (60.87%) | 9 (39.13%) | ||
| III | 32 | 16 (50%) | 16 (50%) | ||
| IV | 1 | 0 | 1 (100%) | ||
| N-category (n = 77) |
0 | 34 | 19 (55.88%) | 15 (44.12%) | 0.539 |
| I | 43 | 21 (48.84%) | 22 (51.16%) | ||
| M-category (n = 73) |
0 | 66 | 32 (48.48%) | 34 (51.52%) | 0.063 |
| I | 10 | 8 (80%) | 2 (20%) | ||
| Neo-adjuvant therapy | Yes | 32 | 17 (53.13%) | 15 (46.87%) | 0.862 |
| No | 45 | 23 (51.11%) | 22 (48.89%) | ||
| Relapse | Yes | 36 | 19 (52.78%) | 17 (47.22%) | 0.891 |
| No | 41 | 21 (51.22%) | 20 (48.78%) | ||
| Tumor type (histological) (n = 73) |
Adenocarcinoma SCC | 39 | 16 (41%) | 23 (59%) | 0.065 |
| 37 | 23 (62.16%) | 14 (37.84%) | |||